Analysts expect that Aduro BioTech Inc (NASDAQ:ADRO) will post $4.73 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Aduro BioTech’s earnings, with the lowest sales estimate coming in at $3.50 million and the highest estimate coming in at $5.80 million. Aduro BioTech posted sales of $2.76 million in the same quarter last year, which suggests a positive year-over-year growth rate of 71.4%. The business is scheduled to issue its next earnings report on Wednesday, February 26th.
On average, analysts expect that Aduro BioTech will report full-year sales of $17.98 million for the current financial year, with estimates ranging from $15.83 million to $19.40 million. For the next financial year, analysts forecast that the company will report sales of $18.93 million, with estimates ranging from $14.00 million to $25.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. The firm had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.55 million. Aduro BioTech had a negative net margin of 544.94% and a negative return on equity of 78.64%.
ADRO opened at $1.10 on Friday. The firm’s 50 day moving average is $1.04 and its 200-day moving average is $1.72. The company has a quick ratio of 7.26, a current ratio of 7.26 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $87.76 million, a P/E ratio of -0.95 and a beta of 1.48. Aduro BioTech has a 52-week low of $0.90 and a 52-week high of $4.59.
In other news, CEO Stephen T. Isaacs sold 31,098 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $1.31, for a total transaction of $40,738.38. Following the sale, the chief executive officer now owns 295,926 shares in the company, valued at $387,663.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 52,185 shares of company stock valued at $68,362 over the last quarter. Corporate insiders own 5.20% of the company’s stock.
Several hedge funds have recently made changes to their positions in ADRO. BlackRock Inc. boosted its stake in Aduro BioTech by 4.4% in the 2nd quarter. BlackRock Inc. now owns 5,225,866 shares of the biotechnology company’s stock valued at $8,046,000 after purchasing an additional 220,010 shares during the period. Baillie Gifford & Co. increased its stake in shares of Aduro BioTech by 6.2% in the 2nd quarter. Baillie Gifford & Co. now owns 4,070,724 shares of the biotechnology company’s stock worth $6,269,000 after purchasing an additional 239,298 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Aduro BioTech by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,517,136 shares of the biotechnology company’s stock worth $3,876,000 after purchasing an additional 55,261 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Aduro BioTech by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,812,200 shares of the biotechnology company’s stock worth $2,791,000 after purchasing an additional 653,600 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Aduro BioTech by 196.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,414,065 shares of the biotechnology company’s stock worth $2,474,000 after purchasing an additional 937,166 shares in the last quarter. Institutional investors own 41.55% of the company’s stock.
About Aduro BioTech
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Featured Article: Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.